Possible chondroprotective effect of canakinumab: An in vitro study on human osteoarthritic chondrocytes

Cytokine

Volumn 71, Issue 2, 2015, Pages 165-172

  Cheleschi, Sara ^a   Cantarini, Luca ^a   Pascarelli, Nicola Antonio ^a   Collodel, Giulia ^b   Lucherini, Orso Maria ^a   Galeazzi, Mauro ^a   Fioravanti, Antonella ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Canakinumab; Human chondrocytes; Osteoarthritis; Tumor necrosis factor

Indexed keywords

CANAKINUMAB; INDUCIBLE NITRIC OXIDE SYNTHASE; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; NITRIC OXIDE; PROTECTIVE AGENT; PROTEOGLYCAN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICULAR CARTILAGE; CARTILAGE CELL; CELL CULTURE; CELL SURVIVAL; DRUG EFFECTS; FEMUR HEAD; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; NECROSIS; OSTEOARTHRITIS; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ANTIBODIES, MONOCLONAL; APOPTOSIS; CARTILAGE, ARTICULAR; CELL SURVIVAL; CELLS, CULTURED; CHONDROCYTES; FEMUR HEAD; GENE EXPRESSION; HUMANS; MATRIX METALLOPROTEINASES, SECRETED; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, FLUORESCENCE; NECROSIS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OSTEOARTHRITIS; PROTECTIVE AGENTS; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84910001726     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.10.023     Document Type: Article

References (53)

1. Martel-Pelletier J.M. Pathophysiology of osteoarthritis. Osteoarthtritis Cartilage 2004, 12:S3-S31.
2. Goldring M.B., Marcu K.B. Cartilage homeostasis in health and rheumatic diseases. Arthritis Res Ther 2009, 11:224.
3. Goldring S.R. Role of bone in osteoarthritis pathogenesis. Med Clin North Am 2009, 93:25-35.
4. Blanco Garcia F.J. Catabolic events in osteoarthritic cartilage. Osteoarthritis Cartilage 1999, 7:308-309.
5. Goldring S.R., Goldring M.B. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Rel Res 2004, 427S:S27-S36.
6. Kobayashi T., Lyons K.M., McMahon A.P., Kronenberg H.M. BMP signaling stimulates cellular differentiation at multiple steps during cartilage development. Proc Natl Acad Sci USA 2005, 102:18023-18027.
7. Goldring M.B., Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol 2011, 23:471-478.
8. Zwerina J., Redlich K., Polzer K., Joosten L., Krönke G., Distler J., et al. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 2007, 104:11742-11747.
9. Kapoor M., Martel-Pelletier J., Lajeunesse D., Pelletier J.P., Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011, 7:33-42.
10. Daheshia M., Yao J.Q. The interleukin 1β pathway in the pathogenesis of osteoarthritis. J Rheumatol 2008, 35:2306-2312.
11. Caramés B., López-Armada M.J., Cillero-Pastor B., Lires-Dean M., Vaamonde C., Galdo F., et al. Differential effects of tumor necrosis factor-alpha and interleukin-1beta on cell death in human articular chondrocytes. Osteoarthritis Cartilage 2008, 16:715-722.
12. Wang Y., Li de L., Zhang X.B., Duan Y.H., Wu Z.H., Hao D.S., et al. Increase of TNFα-stimulated osteoarthritic chondrocytes apoptosis and decrease of matrix metalloproteinases 9 by NF-κB inhibition. Biomed Environ Sci 2013, 26:277-283.
13. Séguin C.A., Bernier S.M. TNF-alpha suppresses link protein and type II collagen expression in chondrocytes: role of MEK1/2 and NF-κB signaling pathways. J Cell Physiol 2003, 197:356-399.
14. Stabellini G., De Mattei M., Calastrini C., Gagliano N., Moscheni C., Pasello M., et al. Effects of interleukin-1β on chondroblast viability and extracellular matrix changes in bovine articular cartilage explants. Biomed Pharmacother 2003, 57:314-319.
15. Goldring M.B., Birkhead J., Sandell I.J., Kimura T., Krane S.M. Interleukin 1 suppresses expression of cartilage-specific types II and IX collagens and increases types I and III collagens in human chondrocytes. J Clin Invest 1988, 82:2026-2037.
16. Chevalier X., Eymard F., Richette P. Biologic agents in osteoarthritis: hopes and disappointments. Nat Rev Rheumatol 2013, 9:400-410.
17. Martel-Pelletier J., Wildi L.M., Pelletier J.P. Future therapeutics for osteoarthritis. Bone 2012, 51:297-311.
18. Jotanovic Z., Mihelic R., Sestan B., Dembic Z. Role of interleukin-1 inhibitors in osteoarthritis: an evidence-based review. Drugs Aging 2012, 29:343-358.
19. Le Graverand-Gastineau M.P. Disease modifying osteoarthritis drugs: facing development challenges and choosing molecular targets. Curr Drug Targets 2010, 11:528-535.
20. Caron J.P., Fernandes J.C., Martel-Pelletier J., Tardif G., Mineau F., Geng C., et al. Chondroprotective effect of intra-articular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum 1996, 39:1535-1544.
21. Pelletier J.P., Caron J.P., Evans C., Robbins P.D., Georgescu H.I., Jovanovic D., et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997, 40:1012-1019.
22. Fernandes J., Tardif G., Martel-Pelletier J., Lascau-Coman V., Dupuis M., Moldovan F., et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol 1999, 154:1159-1169.
23. Dhimolea E. Canakinumab. MAbs 2010, 2:3-13.
24. Church L.D., McDermott M.F. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 2009, 11:81-89.
25. Joosten L.A., Netea M.G., Fantuzzi G., Koenders M.I., Helsen M.M., Sparrer H., et al. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum 2009, 60:3651-3662.
26. Noe A, Howard C, Thuren T, Taylor A, Skerjanec A. Pharmacokinetic and pharmacodynamic characteristics of single-dose canakinumab in patients with type 2 diabetes mellitus. Clin Ther 2014; pii: S0149-2918(14)00535-9 [Epub ahead of print].
27. Dinarello C.A., Simon A., van der Meer J.W. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012, 11:633-652.
28. Moltò A., Olivé A. Anti-IL-1 molecules: new comers and new indications. Joint Bone Spine 2010, 77:102-107.
29. Altman R., Alarcón G., Appelrouth D., Bloch D., Borenstein D., Brandt K., et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991, 34:505-514.
30. Ciliero-Pastor B., Ruiz-Romero C., Caramés B., Lopez-Armada M.J., Blanco F.J. Proteomic analysis by two-dimensional electrophoresis to identify the normal human chondrocyte proteome stimulated by tumor necrosis factor alpha and interleukin-1beta. Arthritis Rheum 2010, 62:802-814.
31. Chen C.N., Li Y.S.J., Yeh Y.T., Lee P.L., Usami S., Chien S., et al. Synergistic roles of platelet-derived growth factor-bb and interleikin-1-beta in phenotypic modulation of human aortic smooth muscle cells. Proc Nat Acad Sci 2006, 103:2665-2670.
32. Heinegard D., Saxne T. Connective tissue macromolecules as markers for tissue processes in joint disease. Eur J Rheumatol 1991, 11:91-99.
33. Gross S.S., Jaffee E.A., Levi R., Kilbourn R.E. Cytokine-activated endothelial cells express an isotope of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages. Biochem Biophys Res Commun 1991, 178:823-829.
34. Smeets R.L., Veenbergen S., Arntz O.J., Bennink M.B., Joosten L.A.B., van den Berg W.B., et al. A novel role for suppressor of cytokine signaling 3 in cartilage destruction via induction of chondrocyte desensitization toward insulin-like growth factor. Arthritis Rheum 2006, 54:1518-1528.
35. Fioravanti A., Moretti E., Scapigliati G., Chellini F., Cervone R., Galeazzi M., et al. Morphological, immunocytochemical and biochemical studies in human osteoarthritic chondrocytes exposed to IL-1β and cyclical hydrostatic pressure. Clin Exp Rheumatol 2007, 25:690-695.
36. Ramakers C., Ruijter J.M., Deprez R.H., Moorman A.F. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 2003, 339:62-66.
37. Pfaffl M.W. A new mathematical model for relative quantification in real RTPCR. Nucleic Acid Res 2001, 29:e45.
38. Dave M., Attur M., Palmer G., Al-Mussawir H.E., Kennish L., Patel J., et al. The antioxidant resveratrol protects against chondrocyte apoptosis via effects on mitochondrial polarization and ATP production. Arthritis Rheum 2008, 58:2786-2797.
39. Fioravanti A., Lamboglia A., Pascarelli N.A., Cheleschi S., Manica P., Galeazzi M., et al. Thermal water of Vetriolo, Trentino, inhibits the negative effect of interleukin 1β on nitric oxide production and apoptosis in human osteoarthritic chondrocytes. J Biol Regul Homeost Agents 2013, 27:891-902.
40. Karnovsky M.G. A formaldehyde-glutaraldehyde fixative of high osmolarity for use in electron microscopy. J Cell Biol 1965, 27:137A.
41. Tonge D.P., Pearson M.J., Jones S.W. The hallmarks of osteoarthritis and the potential to develop personalized disease-modifying pharmacological therapeutics. Osteoarthritis Cartilage 2014, 22:609-621.
42. Lequesne M., Brandt K., Bellamy N., Moskowitz R., Menkès C.J., Pelletier J.P., et al. Guidelines for testing slow-acting and disease-modifying drugs in osteoarthritis. J Rheumatol 1994, 41:65-71.
43. Group for the Respect of Ethics and Excellence in Science (GREES Osteoarthritis Section). Recommendation for the registration of drugs used in the treatment of osteoarthritis. Ann Rheum Dis 1996;55:552-7.
44. Vuolteenaho K., Moilanen T., Hamalainen M., Moilanen E. Effects of TNF-α antagonists on nitric oxide production in human cartilage. Osteoarthritis Cartilage 2002, 10:327-332.
45. Dinarello C.A., Ikejima T., Warner S.J., Orencole S.F., Lonnemann G., Cannon J.G., et al. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol 1987, 139:1902-1910.
46. Caramés B., López-Armada M.J., Cillero-Pastor B. Differential effects of tumor necrosis factor-α and interleukin-1β on cell death in human articular chondrocytes. Osteoarthritis Cartilage 2008, 16:715-722.
47. López-Armada M.J., Caramés B., Lires-Deàn M., Cillero-Pastor B., Ruiz-Romero C., Galdo F., et al. Cytokines, tumor necrosis factor-α and interleukin-1β, differentially regulate apoptosis in osteoarthritis cultured human chondrocytes. Osteoarthritis Cartilage 2006, 14:660-669.
48. Pelletier J.P., Mineau F., Ranger P., Tardif G., Martel-Pelletier J. The increased synthesis of inducible nitric oxide inhibits IL-1ra synthesis by human articular chondrocytes: possible role in osteoarthritic cartilage degradation. Osteoarthritis Cartilage 1996, 4:77-84.
49. Blanco F.J., Ochs R.L., Schwarz H., Lotz M. Chondrocyte apoptosis induced by nitric oxide. Am J Pathol 1995, 146:75-85.
50. Abramson S.B. Osteoarthritis and nitric oxide. Osteoarthr Cartilage 2008, 16:S15-S20.
51. Pelletier J.P., Jovanovic D., Fernandes J.C., Manning P., Connor J.R., Currie M.G., et al. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum 1998, 41:1275-1286.
52. Vuolteenaho K., Moilanen T., Al-Saffar N., Knowles R.G., Moilanen E. Regulation of the nitric oxide production resulting from the glucocorticoid-insensitive expression of iNOS in human osteoarthritic cartilage. Osteoarthritis Cartilage 2001, 9:597-605.
53. Cawston T.E., Young D.A. Proteinases involved in matrix turnover during cartilage and bone breakdown. Cell Tissue Res 2010, 339:221-235.